Equity Overview
Price & Market Data
Price: $1.87
Daily Change: +$0.12 / 6.42%
Range: $1.70 - $1.88
Market Cap: $51,840,328
Volume: 67,410
Performance Metrics
1 Week: 14.02%
1 Month: 2.19%
3 Months: -8.78%
6 Months: 13.33%
1 Year: -18.70%
YTD: -15.00%
Company Details
Employees: 21
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.